Plain-English translation of NCT07684898 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called , a man-made clotting protein designed to help prevent dangerous bleeding episodes in people with severe hemophilia A. The medication works by replacing the missing clotting factor that people with hemophilia A cannot produce on their own. Researchers want to see how well this treatment works, how safe it is, and how long it stays in your body.
People with severe hemophilia A face the constant risk of serious bleeding, which can damage joints and organs. While current treatments help, doctors are looking for new options that may work better or require fewer injections to give patients more freedom and better quality of life.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication to take at home on a regular schedule (typically every 3 days) to prevent bleeding before it starts. Some participants will have extra blood draws in the first week to help doctors understand how the medication works in your body. You'll have regular visits where doctors check how you're doing, measure any bleeding you experience, and monitor your health with blood tests. The study lasts several months, and you'll keep detailed records of any bleeding episodes at home.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China